All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Viale-A trial: Should azacitidine plus venetoclax become SoC for elderly patients with ND AML?

By Claire Baker

Share:

Featured:

Courtney DiNardoCourtney DiNardo

Jun 24, 2020


During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the Viale-A trial. We asked, Should azacitidine + venetoclax become standard of care for elderly patients with newly diagnosed AML?

In the Viale-A trial, patients treated with azacitidine + venetoclax demonstrated significantly improved survival outcomes vs those who received azacitidine alone. Courtney DiNardo suggests that azacitidine + venetoclax is a clinically effective strategy that should be considered as standard of care for elderly patients with newly diagnosed AML.

Viale-A trial: Should azacitidine plus venetoclax become SoC for elderly patients with ND AML?

Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?